Table 3.

Histogenetic subclassification of lymphomas in HIV-infected individuals and clinical outcome reported in the current literature in cART era

HistotypeGCPost-GC
GC B-cell typeActivated B-cell typePlasmablastic type/plasma cell type
BLDLBCL-CBDLBCL-IBPBLPELKSHV + MCD
Phenotypic features       
 CD10 −/+ −/+ − − 
 BCL-6 − − − − 
 MUM1 − − 
 CD138 − − −/+ +/− +/− 
Immunodeficiency From mild————————————————————————————————–→ to severe 
Outcome Improved outcome in cART era Improved outcome in cART era Improved outcome in cART era Poor prognosis Poor prognosis Poor prognosis 
HistotypeGCPost-GC
GC B-cell typeActivated B-cell typePlasmablastic type/plasma cell type
BLDLBCL-CBDLBCL-IBPBLPELKSHV + MCD
Phenotypic features       
 CD10 −/+ −/+ − − 
 BCL-6 − − − − 
 MUM1 − − 
 CD138 − − −/+ +/− +/− 
Immunodeficiency From mild————————————————————————————————–→ to severe 
Outcome Improved outcome in cART era Improved outcome in cART era Improved outcome in cART era Poor prognosis Poor prognosis Poor prognosis 

Histogenetic lymphomas subclassification27,28; reported clinical outcomes.27,28 BL, Burkitt lymphoma; DLBCL-CB, diffuse large B-cell lymphoma, centroblastic variant; DLBCL-IB, diffuse large B-cell lymphoma, immunoblastic variant; PBL, plasmablastic lymphoma; PEL, primary effusion lymphoma; –, absent; +, present; +/− usually present; −/+, usually absent.

Close Modal

or Create an Account

Close Modal
Close Modal